Home > Insider Trading > Filing (0001144204-15-066696)

Filing Details

Accession Number:: 0001144204-15-066696
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-11-18 16:08:43
Reporting Period:: 2015-11-16

Filing Date:: 2015-11-18
Accepted Time:: 2015-11-18 16:08:43
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1293310	Kalobios Pharmaceuticals Inc	KBIO	Pharmaceutical Preparations (2834)	770557236

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1525354	Martin Shkreli	C/O Turing Pharmaceuticals Llc 1177 Avenue Of The Americas, 39Th Floor New York NY 10036		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-11-16	500,169	$0.61	914,254	No	4	P	Direct
Common Stock	Acquisiton	2015-11-16	97,269	$1.43	1,011,523	No	4	P	Direct
Common Stock	Acquisiton	2015-11-17	606,677	$1.93	1,618,200	No	4	P	Direct
Common Stock	Acquisiton	2015-11-17	7,000	$2.43	1,625,200	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Footnotes

The price reported in Column 4 is a weighted average price. Martin Shkreli purchased 500,169 shares in multiple transactions at prices ranging from $0.3 to $.79, inclusive. The reporting person undertakes to provide to Kalobios Pharmaceuticals, Inc., any security holder of Kalobios Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
The securities reported herein are owned directly by Martin Shkreli, who is a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934. There is no voting or ownership agreement amongst the group members and the other members of the group do not have a pecuniary interest in the shares reported herein. Correspondingly, Mr. Shkreli does not have a pecuniary interest in the shares owned by the other members of the group.
The price reported in Column 4 is a weighted average price. Martin Shkreli purchased 606,677 shares in multiple transactions at prices ranging from $1.38 to $2.37, inclusive. The reporting person undertakes to provide to Kalobios Pharmaceuticals, Inc., any security holder of Kalobios Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. Martin Shkreli purchased 7,000 shares in multiple transactions at prices ranging from $2.38 to $2.45, inclusive. The reporting person undertakes to provide to Kalobios Pharmaceuticals, Inc., any security holder of Kalobios Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4.